Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

about

Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Item

http://www.wikidata.org/entity/Q38860997

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Is myeloablative dose intensit ...... transplantation for lymphomas?

@en

type

Item

label

Is myeloablative dose intensit ...... transplantation for lymphomas?

@en

prefLabel

Is myeloablative dose intensit ...... transplantation for lymphomas?

@en

P1476

Is myeloablative dose intensit ...... transplantation for lymphomas?

@en

P2093

A S Kanate

http://www.w3.org/2001/XMLSchema#string

B N Savani

http://www.w3.org/2001/XMLSchema#string

E Ayala

http://www.w3.org/2001/XMLSchema#string

M A Kharfan-Dabaja

http://www.w3.org/2001/XMLSchema#string

M Hamadani

http://www.w3.org/2001/XMLSchema#string

N El-Jurdi

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

Defining the intensity of conditioning regimens: working definitions

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

Postibrutinib outcomes in patients with mantle cell lymphoma.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

P2888

bmt.2017.55

P31

scholarly article

P356

10.1038/BMT.2017.55

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084508953

http://www.w3.org/2001/XMLSchema#string

P698

28368373

http://www.w3.org/2001/XMLSchema#string